Modulating Wnt signaling to improve cell replacement therapy for Parkinson's disease

Journal of Molecular Cell Biology

Volumn 6, Issue 1, 2014, Pages 54-63

  Parish, Clare L ^a   Thompson, Lachlan H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

axon growth; cell transplantation; dopamine; motor function; neurogenesis; Parkinson's disease; Wnt

Indexed keywords

DOPAMINE; WNT PROTEIN;

CELL DIFFERENTIATION; CELL THERAPY; CELL TRANSPLANTATION; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GRAFT SURVIVAL; HUMAN; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; REINNERVATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

AXON GROWTH; CELL TRANSPLANTATION; DOPAMINE; MOTOR FUNCTION; NEUROGENESIS; PARKINSON'S DISEASE; WNT;

ANIMALS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DOPAMINERGIC NEURONS; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE; PLURIPOTENT STEM CELLS; RATS; STEM CELL TRANSPLANTATION; WNT SIGNALING PATHWAY;

EID: 84896900063     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjt045     Document Type: Review

References (83)

1. Andersson, E.R., Prakash, N., Cajanek, L., et al. (2008). Wnt5a regulates ventral midbrain morphogenesis and the development of A9-A10 dopaminergic cells in vivo. PLoS One 3, e3517.
2. Andersson, E.R., Salto, C., Villaescusa, J.C., et al. (2013). Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. Proc. Natl Acad. Sci. USA 110, E602-E610.
3. Barker, R.A., Dunnett, S.B., Faissner, A., et al. (1996). The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Exp. Neurol. 141, 79-93.
4. Barker, R.A., Barrett, J., Mason, S.L., et al. (2013). Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol. 12, 84-91.
5. Bjorklund, A., and Stenevi, U. (1979). Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 177, 555-560.
6. Bjorklund, A., Rosenblad, C., Winkler, C., et al. (1997). Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4, 186-200.
7. Blakely, B.D., Bye, C.R., Fernando, C.V., et al. (2011). Wnt5a regulates midbrain dopaminergic axon growth and guidance. PLoS One 6, e18373.
8. Blakely, B.D., Bye, C.R., Fernando, C.V., et al. (2013). Ryk, a receptor regulating Wnt5a-mediated neurogenesis and axon morphogenesis of ventral midbrain dopaminergic neurons. Stem Cells Dev. 22, 2132-2144.
9. Brundin, P., Karlsson, J., Emgard, M., et al. (2000). Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant. 9, 179-195.
10. Burbach, J.P., Smits, S., and Smidt, M.P. (2003). Transcription factors in the development of midbrain dopamine neurons. Ann. NY Acad. Sci. 991, 61-68.
11. Cajanek, L., Ribeiro, D., Liste, I., et al. (2009). Wnt/beta-catenin signaling blockade promotes neuronal induction and dopaminergic differentiation in embryonic stem cells. Stem Cells 27, 2917-2927.
12. Carlsson, T., Carta, M., Winkler, C., et al. (2007). Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 27, 8011-8022.
13. Castelo-Branco, G., and Arenas, E. (2006). Function of Wnts in dopaminergic neuron development. Neurodegener. Dis. 3, 5-11.
14. Castelo-Branco, G., Wagner, J., Rodriguez, F.J., et al. (2003). Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl Acad. Sci. USA 100, 12747-12752.
15. Castelo-Branco, G., Sousa, K.M., Bryja, V., et al. (2006). Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol. Cell. Neurosci. 31, 251-262.
16. Castilho, R.F., Hansson, O., and Brundin, P. (2000). Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Prog. Brain Res. 127, 203-231.
17. Chung, S., Leung, A., Han, B.S., et al. (2009). Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell 5, 646-658.
18. Ciani, L., and Salinas, P.C. (2005). WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat. Rev. Neurosci. 6, 351-362.
19. Ciani, L., Krylova, O., Smalley, M.J., et al. (2004). A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J. Cell Biol. 164, 243-253.
20. Danielian, P.S., and McMahon, A.P. (1996). Engrailed-1 as a target of the Wnt-1 signalling pathway in vertebrate midbrain development. Nature 383, 332-334.
21. Denham, M., Bye, C., Leung, J., et al. (2012). Glycogen synthase kinase 3beta and activin/nodal inhibition in human embryonic stem cells induces a preneuroepithelial state that is required for specification to a floor plate cell lineage. Stem Cells 30, 2400-2411.
22. Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154-156.
23. Fenstermaker, A.G., Prasad, A.A., Bechara, A., et al. (2010). Wnt/planar cell polarity signaling controls the anterior-posterior organization of monoaminergic axons in the brainstem. J. Neurosci. 30, 16053-16064.
24. Fricker-Gates, R.A., and Dunnett, S.B. (2002). Rewiring the Parkinsonian brain. Nat. Med. 8, 105-106.
25. Gale, E., and Li, M. (2008). Midbrain dopaminergic neuron fate specification: of mice and embryonic stem cells. Mol. Brain 1, 8.
26. Hornykiewicz, O. (1975). Parkinson's disease and its chemotherapy. Biochem. Pharmacol. 24, 1061-1065.
27. Hovakimyan, M., Haas, S.J., Schmitt, O., et al. (2006). Mesencephalic human neural progenitor cells transplanted into the neonatal hemiparkinsonian rat striatum differentiate into neurons and improve motor behaviour. J. Anat. 209, 721-732.
28. Hudson, J.L., Bickford, P., Johansson, M., et al. (1994). Target and neurotransmitter specificity of fetal central nervous system transplants: importance for functional reinnervation. J. Neurosci. 14, 283-290.
29. Ille, F., and Sommer, L. (2005). Wnt signaling: multiple functions in neural development. Cell. Mol. Life Sci. 62, 1100-1108.
30. Joksimovic, M., Yun, B.A., Kittappa, R., et al. (2009). Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. Nat. Neurosci. 12, 125-131.
31. Kauhausen, J., Thompson, L.H., and Parish, C.L. (2013). Cell intrinsic and extrinsic factors contribute to enhance neural circuit reconstruction following transplantation in Parkinsonian mice. J. Physiol. 591, 77-91.
32. Kele, J., Andersson, E.R., Villaescusa, J.C., et al. (2012). SFRP1 and SFRP2 dosedependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cells. Stem Cells 30, 865-875.
33. Kirkeby, A., Grealish, S., Wolf, D.A., et al. (2012). Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 1, 703-714.
34. Kohn, A.D., and Moon, R.T. (2005). Wnt and calcium signaling: beta-cateninindependent pathways. Cell Calcium 38, 439-446.
35. Kordower, J.H., Freeman, T.B., Snow, B.J., et al. (1995). Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332, 1118-1124.
36. Kordower, J.H., Rosenstein, J.M., Collier, T.J., et al. (1996). Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370, 203-230.
37. Kordower, J.H., Freeman, T.B., Chen, E.Y., et al. (1998). Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov. Disord. 13, 383-393.
38. Kriks, S., Shim, J.W., Piao, J., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480, 547-551.
39. L'Episcopo, F., Serapide, M.F., Tirolo, C., et al. (2011a). A Wnt1 regulated Frizzled-1/beta-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol. Neurodegener. 6, 49.
40. L'Episcopo, F., Tirolo, C., Testa, N., et al. (2011b). Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol. Dis. 41, 508-527.
41. Lindvall, O., and Bjorklund, A. (2004). Cell therapy in Parkinson's disease. NeuroRx 1, 382-393.
42. Lindvall, O., Rehncrona, S., Brundin, P., et al. (1989). Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615-631.
43. Logan, C.Y., and Nusse, R. (2004). The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781-810.
44. Maciaczyk, J., Singec, I., Maciaczyk, D., et al. (2008). Combined use of BDNF, ascorbic acid, lowoxygen, and prolonged differentiation time generates tyrosine hydroxylase-expressing neurons after long-term in vitro expansion of human fetal midbrain precursor cells. Exp. Neurol. 213, 354-362.
45. Madrazo, I., Leon, V., Torres, C., et al. (1988). Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N. Engl. J. Med. 318, 51.
46. McMahon, A.P., and Bradley, A. (1990). The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell 62, 1073-1085.
47. Milosevic, J., Brandt, A., Roemuss, U., et al. (2006). Uracil nucleotides stimulate human neural precursor cell proliferation and dopaminergic differentiation: involvement of MEK/ERK signalling. J. Neurochem. 99, 913-923.
48. Nikkhah, G., Bentlage, C., Cunningham, M.G., et al. (1994). Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J. Neurosci. 14, 3449-3461.
49. Olanow, C.W., Kordower, J.H., and Freeman, T.B. (1996). Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19, 102-109.
50. Parish, C.L., and Arenas, E. (2007). Stem-cell-based strategies for the treatment of Parkinson's disease. Neurodegener. Dis. 4, 339-347.
51. Parish, C.L., Castelo-Branco, G., Rawal, N., et al. (2008). Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J. Clin. Invest. 118, 149-160.
52. Perlow, M.J., Freed, W.J., Hoffer, B.J., et al. (1979). Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204, 643-647.
53. Politis, M., Oertel, W.H., Wu, K., et al. (2011). Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov. Disord. 26, 1997-2003.
54. Prakash, N., and Wurst, W. (2006). Development of dopaminergic neurons in the mammalian brain. Cell. Mol. Life Sci. 63, 187-206.
55. Prakash, N., Brodski, C., Naserke, T., et al. (2006). A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development 133, 89-98.
56. Prestoz, L., Jaber, M., and Gaillard, A. (2012). Dopaminergic axon guidance: which makes what? Front. Cell. Neurosci. 6, 32.
57. Rawal, N., Castelo-Branco, G., Sousa, K.M., et al. (2006). Dynamic temporal and cell type-specific expression of Wnt signaling components in the developing midbrain. Exp. Cell Res. 312, 1626-1636.
58. Rawal, N., Parish, C., Castelo-Branco, G., et al. (2007). Inhibition of JNK increases survival of transplanted dopamine neurons in Parkinsonian rats. Cell Death Differ. 14, 381-383.
59. Ribeiro, D., Laguna Goya, R., Ravindran, G., et al. (2012). Efficient expansion and dopaminergic differentiation ofhumanfetal ventral midbrain neuralstemcells by midbrain morphogens. Neurobiol. Dis. 49C, 118-127.
60. Rosso, S.B., and Inestrosa, N.C. (2013). WNT signaling in neuronal maturation and synaptogenesis. Front. Cell. Neurosci. 7, 103.
61. Salinas, P.C., and Zou, Y. (2008). Wnt signaling in neural circuit assembly. Annu. Rev. Neurosci. 31, 339-358.
62. Sanchez-Pernaute, R., Studer, L., Bankiewicz, K.S., et al. (2001). In vitro generation and transplantation of precursor-derived human dopamine neurons. J. Neurosci. Res. 65, 284-288.
63. Sayles, M., Jain, M., and Barker, R.A. (2004). The cellular repair of the brain in Parkinson's disease-past, present and future. Transpl. Immunol. 12, 321-342.
64. Schulte, G., Bryja, V., Rawal, N., et al. (2005). Purified Wnt-5a increases differentiation of midbrain dopaminergic cells and dishevelled phosphorylation. J. Neurochem. 92, 1550-1553.
65. Storch, A., Paul, G., Csete, M., et al. (2001). Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp. Neurol. 170, 317-325.
66. Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
67. Tang, M., Miyamoto, Y., and Huang, E.J. (2009). Multiple roles of beta-catenin in controlling the neurogenic niche for midbrain dopamine neurons. Development 136, 2027-2038.
68. Thomas, K.R., and Capecchi, M.R. (1990). Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature 346, 847-850.
69. Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147.
70. Thompson, L.H., Grealish, S., Kirik, D., et al. (2009). Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur. J. Neurosci. 30, 625-638.
71. Tonnesen, J., Parish, C.L., Sorensen, A.T., et al. (2011). Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. PLoS One 6, e17560.
72. Topol, L., Jiang, X., Choi, H., et al. (2003). Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J. Cell Biol. 162, 899-908.
73. Van den Heuvel, D.M., and Pasterkamp, R.J. (2008). Getting connected in the dopamine system. Prog. Neurobiol. 85, 75-93.
74. Veeman, M.T., Axelrod, J.D., and Moon, R.T. (2003). A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev. Cell 5, 367-377.
75. Wang, W., Shi, L., Xie, Y., et al. (2004a). SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci. Res. 48, 195-202.
76. Wang, X., Li, X., Wang, K., et al. (2004b). Forskolin cooperating with growth factor on generation of dopaminergic neurons from human fetal mesencephalic neural progenitor cells. Neurosci. Lett. 362, 117-121.
77. Wei, L., Sun, C., Lei, M., et al. (2013). Activation of Wnt/beta-catenin pathway by exogenous Wnt1 protects SH-SY5Y cells against 6-hydroxydopamine toxicity. J. Mol. Neurosci. 49, 105-115.
78. Winkler, C., Kirik, D., and Bjorklund, A. (2005). Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci. 28, 86-92.
79. Xi, J., Liu, Y., Liu, H., et al. (2012). Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells 30, 1655-1663.
80. Xia, X.G., Harding, T., Weller, M., et al. (2001). Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 10433-10438.
81. Yurek, D.M. (1997). Intranigral transplants of fetal ventral mesencephalic tissue attenuate D1-agonist-induced rotational behavior. Exp. Neurol. 143, 1-9.
82. Zawada, W.M., Zastrow, D.J., Clarkson, E.D., et al. (1998). Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res. 786, 96-103.
83. Zou, Y. (2004). Wnt signaling in axon guidance. Trends Neurosci. 27, 528-532.